Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 19/20 | 0.73 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521615 | 0.99 | PGR (0.70) | PGRNR3C1NR3C2ARPDE4A | |
| SCHEMBL6426704 | 0.88 | PGR (0.71) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3519246 | 0.85 | PGR (0.74) | PGR | |
| SCHEMBL6424665 | 0.83 | PGR (0.67) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6013866 | 0.83 | PGR (1.00) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3523715 | 0.82 | PGR (0.77) | PGRNR3C1PDE4APDE4BPDE4C | |
| SCHEMBL3520506 | 0.80 | PGR (0.72) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5482190 | 0.80 | PGR (0.72) | PGRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3520044 | 0.80 | PGR (0.72) | PGRNR3C1PDE4APDE4BPDE4C | |
| SCHEMBL5338332 | 0.79 | PGR (0.59) | PGRNR3C1NR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1175398-B1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | WYETH CORP (US) | 2007-07-11 | — | — | EP | claimed |
| US-6544970-B2 | Administering in a first phase of a progestational agent (levonorgestrel or ethinylestradiol) and in a second phase an antiprogestin that is an indolinone derivative, especially a 3-spiroalkylene derivative | WYETH | 2003-04-08 | — | — | US | claimed |
| US-20030050288-A1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2003-03-13 | — | — | US | claimed |
| US-6462032-B1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2002-10-08 | — | — | US | claimed |
| US-6391907-B1 | ANTICANCER AGENTS; CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-05-21 | — | — | US | claimed |
| US-7645761-B2 | Indoline derivatives | WYETH (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070259944-A1 | Indoline derivatives | WYETH (US) | 2007-11-08 | — | — | US | disclosed |
| EP-1175398-B1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | WYETH CORP (US) | 2007-07-11 | — | — | EP | disclosed |
| US-7091234-B2 | Thio-oxindole derivatives | WYETH (US) | 2006-08-15 | — | — | US | disclosed |
| US-7084168-B2 | Indoline derivatives | WYETH (US) | 2006-08-01 | — | — | US | disclosed |
| US-6946454-B2 | Thio-oxindole derivatives | WYETH (US) | 2005-09-20 | — | — | US | disclosed |
| US-20050171186-A1 | 3-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)benzonitrile; 5'-(5-Cyano-1-methyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide; progesterone receptor agonist; mixture with estrone (estrogen); hormone replacement therapy, contraception; anticarcinogenic | WYETH (US) | 2005-08-04 | — | — | US | disclosed |
| US-20030050288-A1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2003-03-13 | — | — | US | disclosed |
| US-6521657-B2 | Indole derivatives which are agonists of the progesterone receptor and useful for treatment of carcinoma and adenocarcinomas of uterine leiomyomata, endometriosis or polycystic ovary syndorme in a mammal | WYETH | 2003-02-18 | — | — | US | disclosed |
| US-20020169198-A1 | Thio-oxindole derivatives | WYETH (US) | 2002-11-14 | — | — | US | disclosed |
| US-6462032-B1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2002-10-08 | — | — | US | disclosed |
| US-20020103248-A1 | Thio-oxindole derivatives | WYETH LLC | 2002-08-01 | — | — | US | disclosed |
| US-20020086874-A1 | Indoline derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-07-04 | — | — | US | disclosed |
| US-6391907-B1 | ANTICANCER AGENTS; CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-05-21 | — | — | US | disclosed |
| US-6355648-B1 | COMPOUNDS AS CONTRACEPTIVES AND PROGESTERONE ANTAGONIST | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259944-A1 | Indoline derivatives | PGR, GNRHR, PRLHR | PGR 1/4885NR3C1 45/4885NR3C2 31/4885 |
| US-20020103248-A1 | Thio-oxindole derivatives | PGR, OXTR, PGRMC1 | PGR 1/4885NR3C1 9/4885NR3C2 7/4885 |
| US-20020086874-A1 | Indoline derivatives | PGR, GNRHR, PRLHR | PGR 1/4885NR3C1 39/4885NR3C2 23/4885 |
| US-20050171186-A1 | 3-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)benzonitrile; 5'-(5-Cyano-1-methyl-1H-pyrrol-2-yl)spiro[cyclohexane-1,3'-[3H]indol]-2'-ylidenecyanamide; progesterone receptor agonist; mixture with estrone (estrogen); hormone replacement therapy, contraception; anticarcinogenic | PGR, ESR1, PGRMC1 | PGR 1/4885NR3C1 20/4885NR3C2 11/4885 |
| US-20020169198-A1 | Thio-oxindole derivatives | GPER1, PGR, ESR1 | PGR 2/4885NR3C1 14/4885NR3C2 8/4885 |
| US-20030050288-A1 | Cyclic regimens utilizing indoline derivatives | PRLHR, GNRHR, BRCA1 | PGR 5/4885NR3C1 178/4885NR3C2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.